MOTS-c as a Potential Diagnostic-prognostic Biomarker for Myocardial Infarction.

Cakmak A, Yazgan B

Cardiovascular & hematological agents in medicinal chemistry1 Jan 2025Cited by 1 (Europe PMC)

PMID40353474DOI10.2174/0118715257368076250324041741PepBankPUB-40353474

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In patients with angiography-defined myocardial infarction, serum MOTS‑c levels did not differ significantly from controls.
In plain wordsIn people with heart attack, the body's own MOTS‑c levels were similar to those of controls.
Peptide
MOTS-c
Outcome
No significant changeSerum MOTS-c, MI versus control
Study
n: not reported in source
Comparator
Control group without obstructive coronary lesions
Outcome group
Mitochondrial function · Cardiovascular
Source sentences
Summary
there was no significant change in MOTS-c levels between the control and the MI group
1 context sentence(design, population, supporting numbers)
Summary · context
For this purpose, patients without obstructive coronary lesions on angiography were included in the control group, while those with significant obstructive coronary lesions on angiography were included in the infarction group.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-4035347401
02HumanEndogenous levelObservational studyOther
In patients with myocardial infarction, serum MOTS‑c levels changed over time (day 0, day 3 and day 30).
In plain wordsIn people with heart attack, the body's own MOTS‑c levels changed over the first 30 days.
Peptide
MOTS-c
Outcome
MixedSerum MOTS-c over time after MI (day 0, 3, 30)
Study
n: not reported in source
Outcome group
Mitochondrial function · Cardiovascular
Source sentences
Summary
while time-dependent changes (day 0, day 3, and day 30) occurred within the MI group.
1 context sentence(design, population, supporting numbers)
Summary · context
For this purpose, patients without obstructive coronary lesions on angiography were included in the control group, while those with significant obstructive coronary lesions on angiography were included in the infarction group.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-4035347402
03HumanEndogenous levelObservational studyOther
In patients with myocardial infarction, serum MOTS‑c correlated negatively with platelet levels at day 0.
In plain wordsIn people with heart attack, higher body's own MOTS‑c levels were linked to lower platelet counts at day 0.
Peptide
MOTS-c
Outcome
DecreaseCorrelation of MOTS-c with platelets at day 0
Study
n: not reported in source
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
However, a negative correlation was found between MOTS-c and platelet levels in the MI group at day 0 (r: -0.4417, p =0.0450).
1 context sentence(design, population, supporting numbers)
Summary · context
For this purpose, patients without obstructive coronary lesions on angiography were included in the control group, while those with significant obstructive coronary lesions on angiography were included in the infarction group.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-4035347403
04HumanEndogenous levelObservational studyOther
In patients with myocardial infarction, serum MOTS‑c correlated negatively with troponin I at day 3.
In plain wordsIn people with heart attack, higher body's own MOTS‑c levels were linked to lower troponin I at day 3.
Peptide
MOTS-c
Outcome
DecreaseCorrelation of MOTS-c with troponin I at day 3
Study
n: not reported in source
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Similarly, MOTS-c was found to be negatively correlated with troponin I in the MI group at day 3 (r: -0.4571, p =0.0372).
1 context sentence(design, population, supporting numbers)
Summary · context
For this purpose, patients without obstructive coronary lesions on angiography were included in the control group, while those with significant obstructive coronary lesions on angiography were included in the infarction group.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-4035347404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.